Simultaneous Single Cell Gene Expression and EGFR Mutation Analysis of Circulating Tumor Cells Reveals Distinct Phenotypes in NSCLC. Issue 8 (23rd July 2020)

• Record Type: Journal Article
• Authors: Owen, Sarah; Lo, Ting‐Wen; Fouladdel, Shamileh; Zeinali, Mina; Keller, Evan; Azizi, Ebrahim; Ramnath, Nithya; Nagrath, Sunitha
• Is Part Of: Advanced biosystems. Volume 4:Issue 8(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-07-23
• Subjects: circulating tumor cells -- digital PCR -- EGFR mutation -- non‐small cell lung cancer -- single cells; Biological systems -- Periodicals; Biotechnology -- Periodicals; Bioengineering -- Periodicals; Biomedical engineering -- Periodicals; Biological Science Disciplines; Periodicals; Periodicals; 660.6
• DOI: 10.1002/adbi.202000110
• Languages: English
• ISSNs: 2366-7478

Abstract

Abstract: While cancer cell populations are known to be highly heterogeneous within a tumor, the current gold standard of tumor profiling is through a tumor biopsy. These biopsies are invasive and prone to missing these clones due to spatial heterogeneity, and this bulk analysis approach can miss information from rare subpopulations. To noninvasively investigate tumor cell heterogeneity, a streamlined workflow is developed to scrutinize rare cells, such as circulating tumor cells (CTCs), for simultaneous analysis of mutations and gene expression profiles at the single cell level. This powerful workflow overcomes low‐input limitations of single cell analysis techniques. The utility of this multiplexed workflow to unravel inter‐ and intra‐patient heterogeneity is demonstrated using non‐small‐cell lung cancer (NSCLC) CTCs ( n = 58) from six epidermal growth factor receptor (EGFR) mutant positive NSCLC patients. CTCs are isolated using a high‐throughput microfluidic technology, the Labyrinth, and their EGFR mutation status and gene expression profiles are characterized. Abstract : Heterogeneous circulating tumor cells (CTCs) are isolated from metastatic non‐small cell lung cancer patients using a label‐free microfluidic device. Single CTC gene expression profiles and epidermal growth factor receptor mutation status are evaluated. Using this dual‐analysis approach, the potential mechanisms of treatment resistance, which may aid in the rational design and testing of novel treatment plans, are identified.